<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of postpartum psychosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of postpartum psychosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of postpartum psychosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Payne, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2154254453"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>During the postpartum period, females are at increased risk of new or recurrent psychiatric illness including mood, anxiety, and psychotic disorders. Postpartum psychosis (or puerperal psychosis) typically presents with rapid onset of psychotic symptoms including hallucinations and delusions, bizarre behavior, confusion, and disorganization which may mimic delirium. Symptom onset is typically within four weeks of delivery.</p><p>The syndrome is most often seen in patients who have been or subsequently are diagnosed with bipolar disorder. Less frequently it occurs in individuals with a diagnosis of major depression with psychosis, schizophrenia, or schizoaffective disorder. Fifty percent or more of females with postpartum psychosis have no prior psychiatric history and in many cases this is the first manifestation of an underlying psychiatric illness [<a href="#rid1">1,2</a>]. A small subset of females experience isolated postpartum psychosis that does not progress to mood or psychotic episodes outside the postpartum time period [<a href="#rid3">3</a>].</p><p>This topic and the associated algorithm discuss the treatment of postpartum psychosis in individuals without a prior diagnosis of a mood disorder (eg, bipolar disorder, major depression with psychosis) or a psychotic disorder  (<a class="graphic graphic_algorithm graphicRef139958" href="/z/d/graphic/139958.html" rel="external">algorithm 1</a>). Treatment of psychosis in the postpartum period in individuals with mood disorder or in individuals with schizophrenia are discussed elsewhere. The epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of postpartum psychosis are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6956.html" rel="external">"Postpartum psychosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17193.html" rel="external">"Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108703.html" rel="external">"Mild to moderate postpartum unipolar major depression: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88582.html" rel="external">"Severe postpartum unipolar major depression: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108715.html" rel="external">"Postpartum unipolar major depression: General principles of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/93451.html" rel="external">"Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5007.html" rel="external">"Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Neonatal outcomes"</a>.)</p><p></p><p class="headingAnchor" id="H3529815916"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Our initial treatment priorities in individuals with postpartum psychosis include ensuring the safety of the patient and their children and initiating medication. Postpartum psychosis constitutes a medical emergency requiring rapid identification and intervention  (<a class="graphic graphic_algorithm graphicRef139958" href="/z/d/graphic/139958.html" rel="external">algorithm 1</a>). (See <a class="local">'Ensure safety'</a> below and <a class="local">'Initiating medication'</a> below.)</p><p>Further discussion of the need for early identification and treatment of postpartum psychosis and assessment of risks to mother and baby are described separately. (See  <a class="medical medical_review" href="/z/d/html/6956.html" rel="external">"Postpartum psychosis: Epidemiology, clinical features, and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/6956.html" rel="external">"Postpartum psychosis: Epidemiology, clinical features, and diagnosis", section on 'Risk of suicide and infanticide'</a>.)</p><p class="headingAnchor" id="H369416906"><span class="h2">Ensure safety</span><span class="headingEndMark"> — </span>Our first priority in all cases of postpartum psychosis is to ensure the safety of the individual and their children. While separation of mother and baby at this critical time is not optimal, we typically hospitalize these individuals. We do not leave the mother alone with their children. An individual experiencing postpartum psychosis will generally not be able to care for themselves or their children without significant support. When the psychosis has lessened to the point that the patient is no longer a risk to themselves or their child, the visitation restrictions are relaxed. In rare cases where the individual’s level of disorganization is mild and a reliable support is available to monitor the individual, we agree to outpatient treatment with daily checks; however, this is the exception. (See  <a class="medical medical_review" href="/z/d/html/6956.html" rel="external">"Postpartum psychosis: Epidemiology, clinical features, and diagnosis", section on 'Risk of suicide and infanticide'</a>.)</p><p>Uncommonly, hospitals may make provisions for supervised daytime visits with the infant. Some countries including the United Kingdom and Australia have inpatient mother-baby psychiatric units, though these units are not widely available internationally.</p><p class="headingAnchor" id="H834737054"><span class="h2">Initiating medication</span></p><p class="headingAnchor" id="H2176908535"><span class="h3">Combined treatment for most</span><span class="headingEndMark"> — </span>Our preferred pharmacologic treatment for individuals with postpartum psychosis who do not have an established psychiatric history is with a combination of an antipsychotic and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid4">4-6</a>]. Our rationale is that individuals with postpartum psychosis have a high likelihood of subsequent diagnosis of bipolar disorder. This differs from our preferred treatment for individuals with psychosis in general (ie, nonpostpartum psychosis) in whom we typically do not begin lithium unless there are clear signs of mood dysregulation (eg, hypomania, mania). Postpartum treatment of individuals with an established psychiatric history is described elsewhere  (<a class="graphic graphic_algorithm graphicRef139958" href="/z/d/graphic/139958.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment", section on 'Psychotic mania'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88582.html" rel="external">"Severe postpartum unipolar major depression: Choosing treatment", section on 'Psychotic depression'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">"Psychosis in adults: Initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14651.html" rel="external">"Bipolar disorder in postpartum women: Epidemiology, clinical features, assessment, and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p>We encourage individuals who plan on breastfeeding (and whose level of psychosis or disorganization does not preclude breastfeeding) to take antipsychotics, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, or antidepressants as indicated. (See <a class="local">'Breastfeeding'</a> below.)</p><p class="headingAnchor" id="H2185316389"><span class="h4">Initiating lithium</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation </strong>– Prior to beginning <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> we screen for renal disease, thyroid dysfunction and obtain an electrocardiogram in individuals with coronary risk factors (eg, diabetes mellitus, hypertension, dyslipidemia, smoking). Further discussion of pretreatment testing for lithium is described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Laboratory tests and monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose, titration, and monitoring </strong>– For individuals without contraindications to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, we typically begin lithium at a dose of 300 mg on the first day then 300 mg two times a day beginning the second day. We check serum lithium levels five days after any adjustment and adjust the dose accordingly. We aim to maintain lithium levels within the established therapeutic window for lithium. Our treatment with lithium, including dose, titration, and monitoring for individuals with postpartum psychosis is the same as treatment with lithium in adults with bipolar disorder. Treatment with lithium in adults with bipolar disorder is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Prescribing lithium'</a> and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H405039432"><span class="h4">Choosing, initiating, and monitoring antipsychotics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing and initiating antipsychotic </strong>– Our choice among antipsychotics is not dependent on the individual’s plan for breastfeeding. Our preference is based on the same factors as those we use in choosing among antipsychotics in nonpostpartum periods. We prefer to treat individuals with a second-generation antipsychotic (SGA) rather than a first-generation antipsychotic. This is based on lower rates of extrapyramidal symptoms [<a href="#rid7">7</a>] and tardive dyskinesia [<a href="#rid8">8</a>] associated with SGAs. Among SGAs our preference is based on patient comorbidity, psychiatric symptoms such as level of agitation, and property of the specific medication that is desired (eg, sedation, weight gain, metabolic dysregulation). Further discussion on selection of antipsychotics is found elsewhere (See  <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">"Psychosis in adults: Initial management", section on 'Selection'</a>.)</p><p></p><p class="bulletIndent1">We titrate from initial dose of the chosen medication to the therapeutic range as quickly as tolerated. For example, in an individual who we are beginning on <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, we typically begin at a dose of 5 to 10 mg, orally, at night. We titrate in 5 mg increments every two days to initial dose range of 10 to 20 mg. We monitor for two or three days and if symptoms persist, we titrate to the maximum oral dose of 30 mg. If using <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a>, we begin at 40 mg daily and titrate to 80 mg daily after three days. We monitor for two or three days and if symptoms persist, we titrate to the maximum oral dose of 160 mg over the next week. We adjust the dose for individuals with hepatic or renal insufficiency. Initial dose and titration of antipsychotic medications are found on the associated table  (<a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For those requiring parenteral formulations</strong> – We use intramuscular (IM) antipsychotics for acute stabilization of individuals who present with agitation or aggression and who are too disorganized to take or refuse to take medications orally. Our preference is to use the first-generation antipsychotic <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>. When using haloperidol we typically use 0.5 to 2 mg IM for mild agitation, 2 to 5 mg IM for moderate agitation and up to 10 mg IM for severe agitation. This can be repeated every 30 minutes until desired level of sedation is achieved. <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> IM is a reasonable alternative. Further discussion of emergency management of agitated or violent adults can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a> and  <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">"Psychosis in adults: Initial management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring on an antipsychotic</strong> – SGAs vary in their side effect profiles. However, the rate of adverse effects from any antipsychotics is comparable to that in nonpuerperal psychotic disorders.</p><p></p><p class="bulletIndent1">Treatment with SGAs is associated with hyperglycemia, hyperlipidemia, and weight gain. Additionally extrapyramidal symptoms have been reported. We monitor individuals treated with antipsychotics for emergent side effects at regular intervals. Adverse effects and monitoring for metabolic dysregulation are discussed elsewhere and presented on the associated tables  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p></p><p class="headingAnchor" id="H1667977516"><span class="h4">Evidence basis for treatment of postpartum psychosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood stabilizers/</strong><strong>lithium</strong><strong> </strong>– Our preference for using <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> in postpartum psychosis is based on clinical trials demonstrating efficacy of mood stabilizers in the treatment of bipolar disorder in nonpostpartum females, reports of successful treatment with lithium in postpartum psychosis, and our clinical experience [<a href="#rid5">5,9</a>].</p><p></p><p class="bulletIndent1">In a retrospective report including 64 in-patients who received stepped care for postpartum psychosis, 47 of the 48 individuals who did not respond to acute treatment with benzodiazepines and antipsychotics remitted following the addition of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid5">5</a>]. Of those that continued lithium monotherapy or augmentation for nine months, 83 percent showed sustained remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotics </strong>– Our preference for using antipsychotic medications in the treatment of females with postpartum psychosis is based on published reports suggest their use is common and effective in treating the syndrome, and our clinical experience [<a href="#rid3">3,10</a>]. Evidence is limited to small uncontrolled studies or case reports [<a href="#rid5">5</a>]. Indirect evidence includes randomized trials of medications for the underlying psychotic disorders in nonpostpartum samples [<a href="#rid11">11-14</a>]. There are no known differences among antipsychotics in their efficacy for reducing psychosis. Efficacy of antipsychotics in the treatment of psychosis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">"Psychosis in adults: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p></p><p class="headingAnchor" id="H517429881"><span class="h3">Monotherapy for specific circumstances</span></p><p class="headingAnchor" id="H2133046750"><span class="h4">Individuals who cannot take lithium</span><span class="headingEndMark"> — </span>For individuals who cannot take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (eg, renal insufficiency) we begin treatment with an SGA as monotherapy at the same dose and titration schedule described above (see <a class="local">'Choosing, initiating, and monitoring antipsychotics'</a> above). Subsequent treatment for inadequate response in individuals who cannot take lithium is discussed below. (See <a class="local">'Inadequate response to monotherapy'</a> below.)</p><p class="headingAnchor" id="H3234718259"><span class="h4">Individuals with mild level of disorganization</span><span class="headingEndMark"> — </span>For individuals with mild levels of disorganization that do not lead to agitation, insomnia or other psychosocial disruption we occasionally begin treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> monotherapy. These individuals may not require an antipsychotic. This is the exception rather than the rule. We monitor these individuals closely while on lithium. We check regular serum levels and adjust lithium accordingly. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Medication doses and side effects'</a>.)</p><p class="headingAnchor" id="H3543084577"><span class="h3">For individuals with concurrent depressive symptoms</span><span class="headingEndMark"> — </span>For individuals without a prior psychiatric history who present with postpartum psychosis with prominent symptoms of major depression (eg, anhedonia, decreased appetite, thoughts of self-harm), our preference is treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, an antipsychotic and an antidepressant (ie, selective serotonin reuptake inhibitor [SSRI]). In these cases, to avoid beginning all three medications at once, we begin with lithium and the antipsychotic and monitor for one week. At that time, unless symptoms are adequately treated, we add the SSRI.</p><p>However, in individuals with emotional lability (rapid fluctuations in mood) or excessive irritability we do not add an SSRI. These symptoms may reflect a mixed state or (ie, mixed depression and mania) or rapidly cycling moods. We are extremely vigilant to identify these patients, as addition of an antidepressant may precipitate a manic episode. (See  <a class="medical medical_review" href="/z/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Risk of switching to mania'</a>.)</p><p>Our choice among the antidepressants are the SSRIs. Our preference from among SSRIs is partially determined by whether the individual will be breastfeeding. The literature on using SSRIs are generally reassuring regarding short-term adverse effects [<a href="#rid15">15,16</a>]. Among the SSRIs our preference is treatment with <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>; however, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> is a reasonable alternative. Both sertraline and fluoxetine are among the most widely studied medications and appear to be associated with few adverse effects in infants exposed through breast milk [<a href="#rid15">15,17</a>]. Exposure to SSRI antidepressant medications in breast milk in general appears to be low and with minimal adverse effects [<a href="#rid18">18,19</a>]. (See <a class="local">'Breastfeeding'</a> below and  <a class="medical medical_review" href="/z/d/html/1720.html" rel="external">"Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding"</a>.)</p><p>Clinical trials have found the combination of an antidepressant and antipsychotic to be efficacious in nonpostpartum patients with major depression with psychotic features [<a href="#rid20">20-24</a>].</p><p class="headingAnchor" id="H1208843906"><span class="h1">SUBSEQUENT TREATMENT</span><span class="headingEndMark"> — </span>An algorithm discusses the treatment of postpartum psychosis  (<a class="graphic graphic_algorithm graphicRef139958" href="/z/d/graphic/139958.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1940556044"><span class="h2">For robust response</span><span class="headingEndMark"> — </span>For individuals who have responded to treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and a second-generation antipsychotic (SGA) we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotic </strong>– We continue treatment with the antipsychotic for a minimum of three to six months. Our decision is based on ongoing stability of symptoms in the context of stable psychosocial functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong><strong> </strong>– We continue <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> monotherapy for up to a year in most cases. At least one cohort study supports the use of lithium for at least nine months, suggesting that the rate of sustained remission is higher for individuals maintained on lithium than those maintained on antipsychotic [<a href="#rid5">5</a>].</p><p></p><p>Individuals who have responded to pharmacologic treatment who discontinue their medication soon after hospital discharge are at increased risk for recurrence.</p><p>In individuals with prior underlying psychiatric history or in those with risk factors such as suicidality, we often treat indefinitely. Discussion of maintenance treatment for bipolar disorder, mood disorders, or psychotic disorders is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a> and  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a> and  <a class="medical medical_review" href="/z/d/html/16596.html" rel="external">"Unipolar major depression with psychotic features: Maintenance treatment and course of illness"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive psychotherapy</strong> – Once the psychotic symptoms are under control, we recommend adjunctive psychotherapy. In our clinical experience, psychotherapy can provide useful adjunctive treatment, focusing on psychoeducation, support, coordination, and encouraging/monitoring adherence to medication. We coordinate with other providers to ensure a coherent uniform plan for monitoring the individual’s status and reinforcing the need for medication adherence.</p><p></p><p class="bulletIndent1">There are no clinical trials investigating the role of psychotherapy or other psychosocial treatments in postpartum psychosis.</p><p></p><p class="headingAnchor" id="H1770044467"><span class="h2">For inadequate response</span></p><p class="headingAnchor" id="H637612699"><span class="h3">Inadequate response to monotherapy</span><span class="headingEndMark"> — </span>For individuals who have begun on monotherapy (see <a class="local">'Monotherapy for specific circumstances'</a> above) our subsequent treatment is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For individuals started on </strong><strong>lithium</strong><strong> monotherapy </strong>–<strong> </strong>For individuals who have started on <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> monotherapy (rather than combined treatment with an antipsychotic), who do not respond to lithium monotherapy despite therapeutic trial, we add an SGA. (See <a class="local">'Monotherapy for specific circumstances'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For individuals started on SGA monotherapy</strong> – For individuals who are unable to take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> who do not respond to treatment with an SGA monotherapy, our next choice is <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>. Valproate is efficacious in nonpostpartum individuals with bipolar disorder. While little evidence supports significant clinical effect on newborn exposure to valproate in breast milk, our preference is to avoid using valproate beyond the initial stabilization period due to teratogenicity in future pregnancy. (See <a class="local">'Breastfeeding'</a> below and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Anticonvulsants'</a>.)</p><p></p><p class="headingAnchor" id="H2358151229"><span class="h3">Prominent insomnia</span><span class="headingEndMark"> — </span>For patients with postpartum psychosis who experience insomnia/disrupted sleep or agitation despite treatment with antipsychotic medication and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, we suggest augmentation with a benzodiazepine rather than other medications. Early intervention to promote sleep in postpartum psychosis may attenuate the psychotic episode.</p><p>In selecting among benzodiazepines, we favor those with a short half-life and no active metabolites, such as <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> [<a href="#rid25">25,26</a>]. Our preference is to begin lorazepam at a dose of 0.5 to 2 mg orally or intramuscularly in conjunction with the antipsychotic.</p><p>Our preference for benzodiazepines in the treatment of prominent insomnia in the context of postpartum psychosis comes from case reports, small studies and our clinical experience supporting their use, particularly to promote sleep, in psychosis and mania [<a href="#rid27">27</a>]. A retrospective report described treatment of 64 inpatients treated for postpartum psychosis using a four-step algorithm: beginning with benzodiazepines, followed by the addition of antipsychotics, then <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, then electroconvulsive therapy (ECT). Only 6 percent of patients responded to benzodiazepine treatment alone; a majority of patients responded to a combination of medications including benzodiazepines [<a href="#rid5">5</a>]. Benzodiazepines are considered relatively safe during breastfeeding, though sedation is a potential side effect in the infant.</p><p>Further information about the safety of benzodiazepines the management of psychosis and in individuals who are breast feeding is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1720.html" rel="external">"Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">"Psychosis in adults: Initial management"</a>.)</p><p class="headingAnchor" id="H2442715179"><span class="h3">For inadequate response to combination therapy</span><span class="headingEndMark"> — </span>For patients with postpartum psychosis who do not respond to antipsychotic medication and mood stabilizers, we often change to another SGA medication while simultaneously beginning to discuss and arrange treatment with ECT [<a href="#rid5">5</a>]. (See <a class="local">'Choosing, initiating, and monitoring antipsychotics'</a> above.)</p><p>Response to ECT is generally more rapid compared with response to medication; thus, ECT may be useful if a rapid response is needed to prevent harm (eg, the woman is at high risk for suicide or infanticide, is catatonic, or is acutely agitated). The number of treatments will depend on the severity of the symptoms.</p><p>There are no randomized clinical trials on the efficacy of ECT in postpartum psychosis. Clinical trials have found ECT to be efficacious in the treatment of nonpostpartum patients with major depression [<a href="#rid28">28-31</a>], to suggest efficacy for bipolar depression [<a href="#rid32">32,33</a>], and to show mixed results for bipolar mania [<a href="#rid34">34-38</a>]. (See  <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)", section on 'Efficacy'</a>.)</p><p>Data from an uncontrolled trial, two retrospective matched-cohort studies, and case series, totaling more 300 patients treated with ECT for postpartum psychosis, provide preliminary support for efficacy [<a href="#rid39">39-42</a>]. As an examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, ECT was associated with a higher rate of “marked improvement” or symptom resolution among 58 females with postpartum psychosis compared with 56 matched nonpuerperal females with psychosis (65 versus 33 percent) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study using the Swedish nationwide population-based registry, ECT was associated with a higher response rate among 185 females who received treatment within six months of giving birth compared with 185 matched nonpuerperal females (87 versus 74 percent) [<a href="#rid43">43</a>]. The risk of relapse after ECT was found to be lower for 180 patients with puerperal psychiatric illness compared with the risk in 180 matched nonpuerperal females, although the risk of relapse was still substantial in both groups [<a href="#rid44">44</a>].</p><p></p><p>ECT has a relatively low rate of adverse effects in the general population, including time-limited neurocognitive effects, rare cardiovascular or pulmonary compromise, and risks associated with general anesthesia [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy"</a>.)</p><p class="headingAnchor" id="H3305183512"><span class="h1">BREASTFEEDING</span><span class="headingEndMark"> — </span>Based upon the limited evidence and our clinical experience, we encourage females with postpartum psychosis who plan on breastfeeding to take antipsychotic medications, antidepressants, or <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> as indicated. Some females will only take their medications if they are allowed to breastfeed. In such cases, the benefits of medication may supersede concerns about use of the drug in lactation.</p><p>However, some females with more severe illness may be too disorganized or present too great a risk to the child to safely breastfeed.</p><p>While all psychotropic medications taken by the mother are transferred into breast milk and are passed on to the nursing infant, the exposure to antipsychotic and antidepressant medications in breast milk appears to be low and clinically insignificant [<a href="#rid18">18,19</a>].</p><p>There is no clear consensus on the safety of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> in breastfeeding females [<a href="#rid45">45</a>]. We use lithium in individuals who can participate in a discussion of the risks and benefits of using the medication while breastfeeding.</p><p>The effects of antipsychotics, benzodiazepines, anticonvulsants, and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> on exposure through breast milk are discussed elsewhere. The literature remains scant and more research is needed to make evidence based recommendations [<a href="#rid46">46</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1720.html" rel="external">"Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/93451.html" rel="external">"Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Breastfeeding'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88582.html" rel="external">"Severe postpartum unipolar major depression: Choosing treatment", section on 'Choosing treatment for breastfeeding patients'</a>.)</p><p></p><p>There are no known effects of electroconvulsive therapy (ECT) on breast milk. The American Psychiatric Association Task Force on ECT recommends that the informed consent process include a discussion with the mother of potential risks to the infant from breastfeeding during a course of ECT [<a href="#rid47">47</a>]. Anesthetic medications administered during ECT treatment generally pose little risk to breastfeeding infants [<a href="#rid48">48</a>]. Exposure can be minimized by delaying breastfeeding for a few hours after ECT therapy or by collecting and storing breast milk the day prior to ECT. Further discussion of ECT in the postpartum period can be found elsewhere (See  <a class="medical medical_review" href="/z/d/html/88582.html" rel="external">"Severe postpartum unipolar major depression: Choosing treatment", section on 'Choosing treatment for breastfeeding patients'</a>.)</p><p class="headingAnchor" id="H3106518439"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a>.)</p><p class="headingAnchor" id="H2992587378"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum psychosis</strong> – Postpartum psychosis presents with rapid onset of psychotic symptoms including hallucinations and delusions, bizarre behavior, confusion, and disorganization. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Postpartum psychosis is most often seen in individuals who have been or subsequently are diagnosed with bipolar disorder. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ensure safety</strong> – Postpartum psychosis constitutes a medical emergency, generally requiring rapid identification and intervention.</p><p></p><p class="bulletIndent1">We typically hospitalize individuals with postpartum psychosis. While separation of mother and baby at this critical time is not optimal, we do not leave the mother alone with their children. (See <a class="local">'Ensure safety'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiating medication</strong> – An algorithm discusses the treatment of postpartum psychosis  (<a class="graphic graphic_algorithm graphicRef139958" href="/z/d/graphic/139958.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined treatment for most</strong> – For individuals with postpartum psychosis with no established psychiatric history, we suggest initial treatment with a combination of an antipsychotic medication and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, rather than either treatment alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Combined treatment for most'</a> above.)</p><p></p><p class="bulletIndent2">As in other settings, we prefer treatment with a second-generation antipsychotic (SGA) rather than a first generation antipsychotic due to their lower rate of extrapyramidal symptoms. (See <a class="local">'Choosing, initiating, and monitoring antipsychotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monotherapy for specific circumstances</strong> – We use an antipsychotic as monotherapy for those who cannot take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>. We infrequently use lithium monotherapy for individuals with very mild disorganization that does not cause psychosocial disruption. (See <a class="local">'Monotherapy for specific circumstances'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For individuals with concurrent depression</strong> – For individuals with postpartum psychosis and prominent symptoms of depression, we suggest combination treatment with a selective serotonin reuptake inhibitor (SSRI) in addition to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and an antipsychotic (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">However, we do not treat individuals with emotional lability or excessive irritability with an SSRI, as these individuals may be at increased risk for precipitating a manic episode. (See <a class="local">'For individuals with concurrent depressive symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For robust response </strong>–<strong> </strong>For individuals with a robust response to treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and an SGA, we continue the antipsychotic for a minimum of three to six months and lithium for a minimum of nine months.</p><p></p><p class="bulletIndent2">For individuals that respond to initial pharmacologic management, we suggest adjunctive psychotherapy focusing on psychoeducation and encouraging adherence to medication (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'For robust response'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For inadequate response to monotherapy</strong> – We add an SGA for individuals who do not respond to initial monotherapy treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>. (See <a class="local">'Inadequate response to monotherapy'</a> above.)</p><p></p><p class="bulletIndent2">For individuals who are unable to take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> who do not respond to initial treatment with SGA monotherapy, our next choice is <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>. We avoid using valproate beyond the initial stabilization period. (See <a class="local">'Inadequate response to monotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For prominent insomnia </strong>– For patients with postpartum psychosis who experience insomnia/disrupted sleep despite initial treatment, we suggest augmentation with a benzodiazepine rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prominent insomnia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For inadequate response to combined treatment </strong>– For patients with postpartum psychosis who do not respond to or tolerate combined treatments, we often change to another SGA medication while simultaneously beginning to arrange treatment with electroconvulsive therapy. (See <a class="local">'For inadequate response to combination therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding </strong>–<strong> </strong>Based upon the limited evidence and our clinical experience, we encourage females with postpartum psychosis who plan on breastfeeding to take antipsychotic medications, antidepressants, or mood stabilizers as indicated. However, some females with more severe illness may be too disorganized or present too great a risk to the child to safely breastfeed. (See <a class="local">'Breastfeeding'</a> above and <a class="local">'Combined treatment for most'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Blackmore ER, Rubinow DR, O'Connor TG, et al. Reproductive outcomes and risk of subsequent illness in women diagnosed with postpartum psychosis. Bipolar Disord 2013; 15:394.</a></li><li><a class="nounderline abstract_t">Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet 2014; 384:1789.</a></li><li><a class="nounderline abstract_t">Wesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis. Am J Psychiatry 2016; 173:117.</a></li><li><a class="nounderline abstract_t">Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt) 2006; 15:352.</a></li><li><a class="nounderline abstract_t">Bergink V, Burgerhout KM, Koorengevel KM, et al. Treatment of psychosis and mania in the postpartum period. Am J Psychiatry 2015; 172:115.</a></li><li><a class="nounderline abstract_t">Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.</a></li><li><a class="nounderline abstract_t">Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31.</a></li><li><a class="nounderline abstract_t">Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry 2017; 78:e264.</a></li><li><a class="nounderline abstract_t">Sani G, Perugi G, Tondo L. Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice? Clin Drug Investig 2017; 37:713.</a></li><li><a class="nounderline abstract_t">Kimmel MC, Lara-Cinisomo S, Melvin K, et al. Treatment of severe perinatal mood disorders on a specialized perinatal psychiatry inpatient unit. Arch Womens Ment Health 2016; 19:645.</a></li><li><a class="nounderline abstract_t">Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999; 19:354.</a></li><li><a class="nounderline abstract_t">Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry 2006; 188:410.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.</a></li><li><a class="nounderline abstract_t">Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951.</a></li><li><a class="nounderline abstract_t">Kronenfeld N, Berlin M, Shaniv D, Berkovitch M. Use of Psychotropic Medications in Breastfeeding Women. Birth Defects Res 2017; 109:957.</a></li><li><a class="nounderline abstract_t">Weisskopf E, Fischer CJ, Bickle Graz M, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opin Drug Saf 2015; 14:413.</a></li><li><a class="nounderline abstract_t">Payne JL. Antidepressant use in the postpartum period: practical considerations. Am J Psychiatry 2007; 164:1329.</a></li><li><a class="nounderline abstract_t">Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl 2015; :1.</a></li><li><a class="nounderline abstract_t">Berle JO, Spigset O. Antidepressant Use During Breastfeeding. Curr Womens Health Rev 2011; 7:28.</a></li><li><a class="nounderline abstract_t">Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838.</a></li><li><a class="nounderline abstract_t">Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24:365.</a></li><li><a class="nounderline abstract_t">Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010; 121:190.</a></li><li><a class="nounderline abstract_t">Müller-Siecheneder F, Müller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18:111.</a></li><li><a class="nounderline abstract_t">Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430.</a></li><li><a class="nounderline abstract_t">Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics 1999; 104:e11.</a></li><li><a class="nounderline abstract_t">Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation : practical recommendations. CNS Drugs 2006; 20:187.</a></li><li><a class="nounderline abstract_t">Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double blind trial. Aust N Z J Psychiatry 1991; 25:238.</a></li><li class="breakAll">FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf (Accessed on May 25, 2011).</li><li><a class="nounderline abstract_t">UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.</a></li><li><a class="nounderline abstract_t">Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003; 19:139.</a></li><li><a class="nounderline abstract_t">Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004; 20:13.</a></li><li><a class="nounderline abstract_t">Goodman WK. Electroconvulsive therapy in the spotlight. N Engl J Med 2011; 364:1785.</a></li><li class="breakAll">FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM240933.pdf (Accessed on April 16, 2014).</li><li><a class="nounderline abstract_t">Loo C, Katalinic N, Mitchell PB, Greenberg B. Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. J Affect Disord 2011; 132:1.</a></li><li class="breakAll">American Psychiatric Association, Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, American Psychiatric Association, Washington, DC 2001.</li><li><a class="nounderline abstract_t">Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Am J Psychiatry 2012; 169:1238.</a></li><li><a class="nounderline abstract_t">Fink M. ECT in therapy-resistant mania: does it have a place? Bipolar Disord 2006; 8:307.</a></li><li><a class="nounderline abstract_t">Kellner CH, Ahle GM, Geduldig ET. Electroconvulsive therapy for bipolar disorder: evidence supporting what clinicians have long known. J Clin Psychiatry 2015; 76:e1151.</a></li><li><a class="nounderline abstract_t">Focht A, Kellner CH. Electroconvulsive therapy (ECT) in the treatment of postpartum psychosis. J ECT 2012; 28:31.</a></li><li><a class="nounderline abstract_t">Babu GN, Thippeswamy H, Chandra PS. Use of electroconvulsive therapy (ECT) in postpartum psychosis--a naturalistic prospective study. Arch Womens Ment Health 2013; 16:247.</a></li><li><a class="nounderline abstract_t">Forray A, Ostroff RB. The use of electroconvulsive therapy in postpartum affective disorders. J ECT 2007; 23:188.</a></li><li><a class="nounderline abstract_t">Reed P, Sermin N, Appleby L, Faragher B. A comparison of clinical response to electroconvulsive therapy in puerperal and non-puerperal psychoses. J Affect Disord 1999; 54:255.</a></li><li><a class="nounderline abstract_t">Rundgren S, Brus O, Båve U, et al. Improvement of postpartum depression and psychosis after electroconvulsive therapy: A population-based study with a matched comparison group. J Affect Disord 2018; 235:258.</a></li><li><a class="nounderline abstract_t">Rönnqvist I, Brus O, Hammar Å, et al. Rehospitalization of Postpartum Depression and Psychosis After Electroconvulsive Therapy: A Population-Based Study With a Matched Control Group. J ECT 2019.</a></li><li><a class="nounderline abstract_t">Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. Eur Neuropsychopharmacol 2016; 26:1562.</a></li><li><a class="nounderline abstract_t">Klinger G, Stahl B, Fusar-Poli P, Merlob P. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev 2013; 10:308.</a></li><li class="breakAll">American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed, American Psychiatric Association, Washington DC 2001.</li><li><a class="nounderline abstract_t">Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.</a></li></ol></div><div id="topicVersionRevision">Topic 6964 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23651079" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Reproductive outcomes and risk of subsequent illness in women diagnosed with postpartum psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455249" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514657" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16724884" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A review of postpartum psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of psychosis and mania in the postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of bipolar disorder during pregnancy and the postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19058842" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146614" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477315" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26802019" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of severe perinatal mood disorders on a specialized perinatal psychiatry inpatient unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648526" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845269" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810019" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28714610" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of Psychotropic Medications in Breastfeeding Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25554364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728416" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antidepressant use in the postpartum period: practical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344706" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of psychotropic drugs during pregnancy and breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22299006" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antidepressant Use During Breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652123" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232326" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19694628" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9555596" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883815" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The pharmacological treatment of delusional depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390297" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16529525" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Use of psychotropic medications in treating mood disorders during lactation : practical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1877960" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clonazepam in acute mania: a double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1877960" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clonazepam in acute mania: a double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642045" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972983" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A meta-analysis of electroconvulsive therapy efficacy in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087991" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of ECT in depression: a meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561344" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Electroconvulsive therapy in the spotlight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561344" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Electroconvulsive therapy in the spotlight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858566" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858566" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212054" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ECT in treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696837" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : ECT in therapy-resistant mania: does it have a place?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26455688" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Electroconvulsive therapy for bipolar disorder: evidence supporting what clinicians have long known.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330704" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Electroconvulsive therapy (ECT) in the treatment of postpartum psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23568390" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of electroconvulsive therapy (ECT) in postpartum psychosis--a naturalistic prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804998" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The use of electroconvulsive therapy in postpartum affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467968" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparison of clinical response to electroconvulsive therapy in puerperal and non-puerperal psychoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29660641" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improvement of postpartum depression and psychosis after electroconvulsive therapy: A population-based study with a matched comparison group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30807499" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rehospitalization of Postpartum Depression and Psychosis After Electroconvulsive Therapy: A Population-Based Study With a Matched Control Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27568278" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724438" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antipsychotic drugs and breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724438" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antipsychotic drugs and breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692973" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The use of electroconvulsive therapy in special patient populations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
